The hepatitis C virus (HCV) is responsible for approximately 50 million infections worldwide.
Effective drug treatments while available face access barriers, and vaccine development is …

Hepatitis C virus (HCV) is responsible for no less than 71 million people chronically infected
and is one of the most frequent indications for liver transplantation worldwide. Despite direct …

BACKGROUND Chronic hepatitis C virus (HCV) infection is characterized by a severe
impairment of HCV-specific CD4+ T cell help that is driven by chronic antigen stimulation …

A prophylactic hepatitis C virus (HCV) vaccine that elicits neutralizing antibodies could be
key to HCV eradication. However, the genetic and antigenic properties of HCV envelope …

Hepatitis C virus (HCV) is one of very few viruses that are either naturally cleared, or
alternatively persist to cause chronic disease. Viral diversity and escape, as well as host …

Background Given the importance of neutralising antibodies in protection against SARS-
CoV-2 infection, it is critical to assess neutralisation persistence long-term following …

Hepatitis C virus (HCV) persistently infects approximately 71 million people globally. To
prevent infection a vaccine which elicits neutralizing antibodies against the virus envelope …

Introduction Early development of broadly neutralizing antibodies (bNAbs) targeting the
hepatitis C virus (HCV) envelope glycoprotein E2 is associated with spontaneous clearance …

Background and aims In individuals highly exposed to hepatitis C virus (HCV), reinfection is
common, suggesting that natural development of sterilising immunity is difficult. In those that …

Introduction Follicular helper T cells are essential for helping in the maturation of B cells and
the production of neutralizing antibodies (NAbs) during primary viral infections. However …